LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
Top Cited Papers
- 30 March 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (4), 929-939
- https://doi.org/10.1002/art.27334
Abstract
Objective We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti–interleukin‐17 (anti–IL‐17) monoclonal antibody, in a first in‐human trial in rheumatoid arthritis (RA) patients taking oral disease‐modifying antirheumatic drugs (DMARDs). Methods This randomized, double‐blind, placebo‐controlled study consisted of 2 parts. In part A, 20 patients received 1 intravenous (IV) dose of LY2439821 (0.06, 0.2, 0.6, or 2.0 mg/kg, escalating) or placebo followed by 8 weeks of evaluation. End points included safety, tolerability, and pharmacokinetics. In part B, 77 patients received 1 IV dose of LY2439821 (0.2, 0.6, or 2.0 mg/kg) or placebo every 2 weeks for a total of 5 doses, with a total evaluation period of 16 weeks. End points included safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score in 28 joints [DAS28] and percentages of patients meeting American College of Rheumatology 20%, 50%, or 70% improvement criteria [achieving an ACR20, ACR50, or ACR70 response]). The primary efficacy end point was the DAS28 at week 10. Results Baseline characteristics were similar across all groups. Changes in the DAS28 were significantly greater in the 0.2 mg/kg, 2.0 mg/kg, and all‐LY2439821–combined groups (−2.3, −2.4, and −2.3, respectively) than in the placebo group (−1.7) at week 10 (P ≤ 0.05), and these differences were significant as early as week 1. Percentages of ACR20, ACR50, and ACR70 responses as well as improvements in the ACR core set of measures were greater in LY2439821‐treated patients than in placebo‐treated patients at multiple time points. There was no apparent dose‐response relationship in treatment‐emergent adverse events. Conclusion LY2439821 added to oral DMARDs improved signs and symptoms of RA, with no strong adverse safety signal noted. This first evaluation of LY2439821 supports neutralization of IL‐17 as a potential novel goal for the treatment of RA.Keywords
This publication has 23 references indexed in Scilit:
- Interleukin-17 and Type 17 Helper T CellsThe New England Journal of Medicine, 2009
- The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidenceCurrent Opinion in Rheumatology, 2007
- The IL-23/Th17 axis: therapeutic targets for autoimmune inflammationCurrent Opinion in Immunology, 2006
- Unmet needs in rheumatoid arthritisArthritis Research & Therapy, 2005
- Cutting Edge: Roles of Toll-Like Receptor 4 and IL-23 in IL-17 Expression in Response toKlebsiella pneumoniaeInfectionThe Journal of Immunology, 2003
- Management of Rheumatoid ArthritisDisease Management and Health Outcomes, 2003
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Rheumatoid arthritisThe Lancet, 2001
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995